Serum and follicular fluid (FF) estradiol (E2) levels in ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) and gamete intrafallopian transfer (GIFT) conception cycles after pituitary suppression.
Initial hope that ovarian hyperstimulation syndrome (OHSS) would be less likely to occur after pituitary suppression with gonadotropin releasing-hormone agonists (GnRH-a) has not been substantiated. GnRH-a/human menopausal gonadotropin (hMG) protocols often lead to OHSS with markedly elevated circulating estradiol (E2) levels in susceptible patients. This study was undertaken to determine whether or not intrafollicular E2 secretion is increased in these cases. Fifty-two in vitro fertilization (IVF) and gamete intrafallopian transfer (GIFT) conception cycles treated with GnRH-a/hMG were included in the study. GnRH-a, leuprolide, 0.5 mg, was administered subcutaneously from day 20 of the preceding cycle and the ovaries were stimulated with hMG, 75-225 IU bid intramuscularly, followed by human chorionic gonadotropin (hCG), 5000 IU. Twenty cycles (Group I) were associated with moderate or severe OHSS and 32 cycles (Group II) did not result in OHSS. E2 was measured in the serum on the day of hCG (day 0), on the day of oocyte retrieval (day 2), and at midluteal phase (days 6-8), as well as in the follicular fluid (FF) using a solid-phase direct RIA. Mean serum E2 was significantly higher at all three sampling times in Group I (OHSS) than in Group II. Both the number of follicles and the number of oocytes were also significantly higher in Group I.(ABSTRACT TRUNCATED AT 250 WORDS)
Leya
J
J
Department of Obstetrics and Gynecology, Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois 60612.
Molo
M W
MW
Olson
D
D
Radwanska
E
E
D000328:Adult; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D004958:Estradiol / Q000032:analysis / Q000097:blood* / Q000378:metabolism; D005260:Female; D005307:Fertilization in Vitro; D015571:Follicular Fluid / Q000737:chemistry* / Q000378:metabolism; D015181:Gamete Intrafallopian Transfer; D007987:Gonadotropin-Releasing Hormone / Q000494:pharmacology; D006801:Humans; D007279:Injections, Subcutaneous; D016729:Leuprolide / Q000494:pharmacology; D008596:Menotropins / Q000494:pharmacology; D016471:Ovarian Hyperstimulation Syndrome / Q000139:chemically induced / Q000378:metabolism* / Q000503:physiopathology; D010902:Pituitary Gland / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology
D006063:Chorionic Gonadotropin; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D008596:Menotropins; D016729:Leuprolide